Last updated: July 30, 2026
INTEGRILIN (Eptifibatide) Clinical Trials Update, Market Landscape, and Revenue Projection (2018-2035)
Integrilin is the brand name for eptifibatide, a short-acting glycoprotein IIb/IIIa inhibitor used as an IV antiplatelet agent in acute coronary syndromes and for PCI adjunct therapy. Sales have been in long-term decline due to reduced use of GP IIb/IIIa inhibitors, uptake of alternative antithrombotic regimens, and generic erosion in core geographies. No new clinical-development program is disclosed at the brand level in major registries in recent years; the market is driven by generic/authorized generics and hospital formulary positioning rather than patent-led innovation.
What is Integrilin (eptifibatide) used for and what outcomes do trials focus on?
Integrilin is used to reduce ischemic events in high-risk acute coronary syndromes and to prevent thrombotic complications during PCI, typically as an adjunct to heparin and aspirin in guideline-based protocols.
Key trial endpoints: what do studies measure?
Common efficacy endpoints across the eptifibatide trial program include:
- Composite death/myocardial infarction (MI)/urgent revascularization at short-term follow-up (often 30 days or 48 hours depending on trial design).
- MI definitions and adjudication consistency for early thrombotic outcomes.
- Procedural endpoints during PCI such as acute vessel closure and ischemic complications.
Safety endpoints repeatedly emphasize:
- Major bleeding as defined in each trial protocol.
- Thrombocytopenia and related discontinuation signals.
Which patient settings dominate evidence?
Evidence is strongest in:
- Non-ST-elevation acute coronary syndromes with biomarker evidence or high-risk features.
- PCI settings, including patients undergoing balloon angioplasty/stenting with adjunct antithrombotic therapy.
What clinical trials updated the efficacy and safety profile of eptifibatide (Integrilin)?
No major “new evidence” trials altering standard-of-care have emerged in the last several years in publicly visible registries at the brand level; the clinical dataset remains anchored to the classic phase III and large randomized studies from the early adoption era.
Landmark trial program summary (clinical evidence base)
The pivotal evidence base includes large controlled trials in ACS and PCI contexts, which established:
- Antithrombotic efficacy as an adjunct to heparin and aspirin.
- A consistent bleeding tradeoff that depends on patient risk, dosing, and concomitant therapies.
How has practice changed since the pivotal trials?
The practical update in clinical use is not new trial readouts but guideline drift and regimen evolution:
- Increased use of P2Y12 inhibitors and anticoagulant strategies that reduce reliance on GP IIb/IIIa agents as default therapy.
- More selective GP IIb/IIIa use in cases such as thrombus-heavy lesions, bailout scenarios, or very high-risk angiographic profiles in centers that still use them.
What is the current FDA and regulatory status of Integrilin?
Integrilin is an older small-molecule IV drug with a well-established label and a mature regulatory history. The commercial market is dominated by generic eptifibatide products in most developed markets where patents are no longer a barrier.
Orange Book status: what does it imply about generics?
The Orange Book listing of eptifibatide-related products reflects the drug’s long-standing market presence. Because Integrilin is not a new molecular entity, generic entry timing is historically shaped by:
- Discontinuation of exclusivity from the original NDA era.
- Patent expirations across formulation, method-of-use, and process claims (where applicable) that typically precede modern generic manufacturing.
Substitution and interchangeability
In routine hospital procurement:
- IV antiplatelet substitution is driven by formulary cost, procurement contracts, and institutional protocols.
- Bioequivalence for generics is typically sufficient for use where allowed, given that therapeutic effect is rapid and dosing is standardized.
How big is the Integrilin market and why is demand declining?
Integrilin’s market is structurally constrained by:
- Short duration of use per course (rapid infusions, limited inpatient window).
- Lower utilization rates in modern ACS/PCI pathways.
- Generic penetration that compresses price and value per treatment.
Market sizing mechanics (demand drivers)
Demand is linked to hospital volume in:
- NSTEMI/unstable angina presentations in settings using GP IIb/IIIa inhibitors selectively.
- PCI volumes and the share of procedures where GP IIb/IIIa is used.
Decline drivers:
- Guideline and protocol shifts away from routine upfront GP IIb/IIIa use.
- Increased preference for alternatives (P2Y12 agents and anticoagulants) that reduce reliance on class members.
What is the competitive landscape for eptifibatide (Integrilin) in generics and authorized generics?
Competitive intensity is high, with generic manufacturers supplying the active ingredient at multiple dosage presentations (depending on local approvals and procurement tenders). In practice, competition is decided by:
- Net price after rebates and contract pricing.
- Availability and manufacturing reliability for IV sterile products.
- Supply chain performance for hospital systems.
Where do procurement risks concentrate?
Risks for manufacturers and brand remnants concentrate in:
- Sterile manufacturing capacity.
- Batch consistency and stability of supply under demand fluctuations tied to PCI/ACS caseload.
- Tender-driven ordering patterns that shift quickly between suppliers.
When does Integrilin lose exclusivity and what patent estate barriers existed historically?
Because Integrilin is an older product with long-standing generic availability, exclusivity windows tied to the original NDA have long expired. The patent landscape in mature phases typically impacts:
- Longer-tail “evergreening” claims such as specific dosing regimens or formulation/process improvements, if any were ever granted and enforced.
- Settlement agreements that historically delayed some generic entries in key markets, though the current market is already established with multiple generic products.
Practical implication
For business planning now, market access is primarily constrained by:
- Regulatory quality and manufacturing approvals.
- Supply contracts and hospital formulary decisions.
- Local exclusivity remnants only if a specific generic entrant obtained a legally protected exclusivity window for a specific presentation.
What patent and litigation issues affected eptifibatide generic entry?
For Integrilin, the relevant litigation and exclusivity timeline is largely a historical driver rather than a current barrier:
- Generic entry has already occurred broadly, meaning most litigation effects are already “priced in” into the supply base.
- Any remaining patent disputes would be presentation-specific or jurisdiction-specific and would likely affect a narrow slice of procurement.
What generic entry risks exist for eptifibatide (Integrilin) today?
For current entrants:
- Risks are less about clinical failure and more about regulatory and supply-chain execution.
- Market share is determined by tender win rates and manufacturing uptime rather than by Paragraph IV strategy.
For incumbents:
- The main risk is commodity-like price compression and contract churn as hospital networks standardize on lower net-cost suppliers.
How do current clinical trends affect eptifibatide (Integrilin) utilization by indication?
ACS (NSTEMI/UA) utilization trend
GP IIb/IIIa inhibitors are more commonly used as:
- Rescue or selective therapy rather than routine upfront use.
- A targeted option for very high thrombus burden or high-risk angiographic features depending on center practice.
PCI utilization trend
GP IIb/IIIa usage during PCI tends to be:
- Case- and lesion-dependent (thrombotic burden, bailout needs).
- More limited in contemporary practice compared with the era when these trials established default workflows.
What is the clinical development outlook for eptifibatide (Integrilin)?
The development outlook is limited by the drug’s maturity:
- No widely signaled “next-gen” eptifibatide program is evident in public registries as a brand-stage catalyst.
- Value creation in this category generally comes from supply and cost optimization rather than from new efficacy claims.
Business implication:
- R&D investment focuses on manufacturing improvements, line extensions, and regulatory maintenance rather than transformative clinical studies.
Revenue projection: what will Integrilin (eptifibatide) earn through 2035?
A robust, defensible forecast requires current global sales baselines by region and a defined channel model. The present request does not provide sales history, net pricing assumptions, or geographic breakdown, so a complete numeric projection cannot be produced without risking fabrication.
What can be stated with decision-grade specificity:
- The market direction is structurally downward or flat-to-down due to low per-patient duration, generic price pressure, and diminished routine utilization.
- Incremental growth is more likely from emerging-market expansion of PCI/ACS volumes than from a re-expansion of GP IIb/IIIa routine use.
- Any growth scenario hinges on selective re-adoption of GP IIb/IIIa in defined high-risk cohorts, which would require new guideline support or demonstrable protocol changes.
Key Takeaways
- Integrilin (eptifibatide) remains an IV GP IIb/IIIa inhibitor with a mature evidence base, but routine utilization has declined versus earlier ACS/PCI workflows.
- The current commercial market is dominated by generics, making price and procurement contracts the main determinants of unit and revenue performance.
- Current “clinical trials updates” are not the primary driver; practice pattern shifts and generic supply economics dominate.
- A numeric revenue projection through 2035 cannot be stated without current baseline sales and regional/price assumptions.
FAQs
- Is eptifibatide still recommended for NSTEMI in current guidelines, and when is it used?
- What are the main bleeding risk factors for eptifibatide, and how do they affect hospital protocols?
- How does eptifibatide compare with abciximab and tirofiban for PCI adjunct therapy?
- What dosing and monitoring considerations drive safe use of eptifibatide in renal impairment?
- What formulation or presentation differences matter for generic substitution in hospitals?
References (APA)
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
